ORIC PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.63 USD | -1.63% |
|
-7.66% | -27.93% |
Presenter SpeechUnknown Analyst (Analysts)All right. Thank you guys so much for joining us her...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its clinical-stage product candidates include ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.
Calendar
2024-08-07
- Q2 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
6.63
USD
Average target price
19
USD
Spread / Average Target
+186.58%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -27.93% | 447M | |
| +16.49% | 122B | |
| +21.73% | 115B | |
| +22.15% | 26.64B | |
| -21.81% | 19.91B | |
| -16.89% | 16.32B | |
| -18.81% | 15.49B | |
| -44.74% | 15.52B | |
| +62.72% | 14.83B | |
| +3.09% | 13.67B |
- Stock Market
- Equities
- ORIC Stock
- News ORIC Pharmaceuticals, Inc.
- Transcript : ORIC Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 10
